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ABSTRACT 
Background: Coffee consumption in relation to female hormone-related cancers has been investigated but meta-
analyses regarding breast and ovarian cancer include studies published up to 2012 with inconsistent results for 
ovarian cancer. 
Methods: We conducted two updated meta-analyses of studies published up to June 2016 to quantify the association 
of coffee intake with breast and ovarian cancer risk with random effects models. We used the dataset developed by 
the International Agency for Research on Cancer Working Group for Monograph 116 meeting (May 2016).  We 
additionally performed a PubMed search in June 2016.  
Results: Summary relative risks (RRs) (95% confidence intervals (CI)) for the study-specific highest vs. lowest coffee 
consumption were for breast and ovarian cancer respectively: 0.97 (0.93–1.00, Ι2 5.5%, 40 studies, 76,728 
cases) and 1.03 (0.93–1.14, Ι2 31.9%, 31 studies, 13,111 cases). For decaffeinated coffee the corresponding 
RRs were: 1.00 (0.93-1.08, I2 32.2%, 13 studies) and 0.83 (0.71-0.96, I2 about 0%, 9 studies). The association 
of coffee with ovarian cancer risk was higher among publications before (RR=1.37, 1.12–1.69) compared to after 
2000 (RR=0.96, 0.86-1.06).
Conclusion: Our meta-analyses provide strong, quantitative evidence that coffee consumption is not related to breast 
cancer risk and appears to be unrelated to ovarian cancer risk.
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INTRODUCTION
Coffee is one of the most frequently consumed 
beverages worldwide [1]. The role of coffee consumption 
on the risk of female hormone-related cancers (i.e. breast, 
ovarian and endometrial cancers) has been investigated 
since the 1980’s [2,3]. The accumulated evidence 
regarding the association of coffee intake with these 
cancers has been also evaluated by international research 
organizations (World Cancer Research Fund (WCRF)/
American Institute for Cancer Research (AICR) [4,5]; 
International Agency for Research on Cancer (IARC), 
Monographs Working Group (WG) [6, 7]). In 2016, the 
IARC Working Group that evaluated the carcinogenicity 
of coffee consumption concluded that there was evidence 
suggesting lack of carcinogenicity for cancers of the 
endometrium and female breast and inadequate evidence 
for ovarian cancer [7].
With respect to endometrial cancer, the up-to-date 
evidence is consistent with a dose-response inverse 
association with increased coffee consumption: this has 
been demonstrated in well conducted earlier meta-
analyses [8], as well as, most recent ones [9]. 
For breast cancer, a few meta-analyses, some 
of which with methodological limitations, have been 
undertaken [10-14]. In the most-informative one [13] the 
meta-RR estimate, from 37 cohort and case–control studies 
published up to 2012, was 0.97 (95% CI 0.93–1.00) for 
the study-specific highest versus lowest coffee consumption, 
and 0.98 (95% CI 0.96–1.00) for an increment of 2 
cups/day. The most-recent meta-analysis [14] included 
only prospective studies published up to July 2012 and 
found no relation overall (meta-RR: 0.99, 95%CI 0.94-
1.04 for the highest versus lowest study-specific intakes). 
For ovarian cancer, the information on the association 
with coffee intake is yet inconclusive. Two older case-
control studies found an over two-fold increased risk 
with higher coffee intake [15, 16], and other studies 
reported non-significantly increased risks. Moreover, the 
four published meta-analyses [11, 14, 17, 18] are not 
fully informative. The most recent one [14], based on 
prospective studies published up to 2012, estimated 
a meta-RR of 1.04 (95% CI: 0.90-1.20) for the study-
specific highest versus lowest coffee intake. The only 
meta-analysis, published in 2007, considering both 
cohort (N=4) and case-control (N=11) studies, found 
meta-RRs of 1.32 (95% CI 0.99, 1.77) and 1.15 (95% 
CI 0.89, 1.47), respectively [17]. 
Since the publication of the previous meta-analyses 
additional epidemiological data have become available. 
Some relevant studies [19-25] have not been considered 
in any of the aforementioned published meta-analyses. In 
this study we conducted two systematic reviews and meta-
analyses to quantitatively evaluate the relation of coffee 
intake with breast and ovarian cancer risk using all articles 
published up to June 2016.
MATERIALS AND METHODS
Study selection
The flow chart for the selection procedure supplementary 
to IARC search is shown in Supplementary Figure 1. 
This search identified 6,352 articles included in the 
PubMed database. On the basis of the titles and abstracts 
6,187 were initially excluded whereas the remaining 165 
were fully examined. From these, the following articles 
were not considered: 83 because they did not report 
information on the association of coffee consumption with 
breast and/or ovarian cancer; 1 study because it reported 
the association between total caffeine (not coffee) and 
breast cancer risk [26]; 3 studies considering coffee only 
together with tea consumption [27-29]; 3 studies on male 
breast cancer [30-32]; 3 studies on BRCA1 or BRCA2 
mutation carriers [33-35]; 3 studies [36-38] which used 
the same study population as more informative studies that 
were included in the meta-analyses [39-41]. 
A total of 68 articles, the same as those considered 
by the Monograph 116 working group, were finally 
selected for the meta-analyses (overall and in specific 
strata) of coffee consumption in association to breast 
(42 articles, based on 41 studies) [3, 19-23, 25, 28, 
40-73] and ovarian cancer risk (32 articles, based on 
32 studies) [2, 3, 15-8, 22, 24, 25, 39, 42, 46, 57, 
69, 74-91]. The sum overcomes the total because six 
cohort [3, 22, 25, 42, 46, 57] and one case-control 
[69] studies reported associations of coffee intake with 
both ovarian and breast cancer risk, and were included 
in both meta-analyses. Detailed characteristics of these 
studies are shown in Table 1, a and b.
Data extraction
For each study, data were extracted on study design, 
country, duration of follow-up (for cohort studies), enrolment 
period, number of subjects (cases and controls/non-cases 
or cohort size), age of the study population, type of 
coffee (e.g., total, regular/caffeinated, decaffeinated), 
coffee-drinking categories, estimates of RR (e.g. HR, 
OR etc.) and their corresponding 95% CIs, number of 
cases/non-cases, or, person(time)-at-risk for each coffee-
drinking category (if available), and covariates adjusted 
for in the analysis. We selected from each study RR 
estimates adjusted for the largest number of confounding 
factors. For case–control studies providing OR estimates 
separately for population and hospital controls, we 
considered the ORs based on population controls [28, 
66]. In the case-control study by Rosenberg et al. [60], 
we selected the ORs for breast cancer based on non-
cancer controls. 
Coffee was assessed in the vast majority of studies 
through Food Frequency Questionnaires (FFQ) enquiring 
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usual coffee intake over a period preceding enrolment 
(e.g. previous year). Most FFQs had been validated for 
dietary intakes, although not necessarily for coffee intake. 
Coffee intake was classified in cups per day, month or 
week in most studies. 
We considered ‘total coffee’ when no further 
details on type or caffeine content were reported; when 
information was available we selected RRs for regular/
caffeinated coffee. For the study by Schairer et al, 
[62], providing RRs of breast cancer for brewed and 
instant caffeinated coffee (but not for total/any coffee), 
we included in the meta-analysis the RR for brewed 
caffeinated coffee, as consumed by more subjects. In the 
Swedish Mammography Cohort [41, 74], RRs for ovarian 
and breast cancer for long-term coffee consumption were 
extracted. 
Statistical analysis
Summary RRs were estimated by combining the 
study-specific RRs comparing the highest versus the lowest 
category of coffee intake using random-effects models to 
take into account the between-study heterogeneity [92]. 
Each study’s log (RR) was weighted by the inverse of its 
variance plus the between-study variance component τ2 
computed by the moment estimator [92]. Heterogeneity 
among studies was evaluated with chi-square test and I2 
statistic [93, 94]. Publication bias was evaluated through 
funnel plots [95] and with the Egger’s and Begg’s tests [96]. 
When a study reported only the number of cases/
non-cases for categories of coffee intake, we computed 
the crude RRs and the corresponding 95% CIs [61, 70, 
86]. Moreover, when a study reported the adjusted 
RRs, but not the corresponding adjusted 95% CIs, we 
used the standard errors of the corresponding crude 
RRs (calculated from the distribution of cases and non-
cases), to obtain the approximate CIs for the reported 
adjusted RRs [39, 42, 46, 65, 79, 80]. The method 
of Hamling et al. [97] was used to convert RR estimates 
when the reference category used in the analyses was 
not the lowest category [21, 23, 54]. In the study by 
Gosvig et al [24], where the RR for the coffee intake 
was reported only by histological type of ovarian 
cancer, we pooled these RRs to estimate the overall 
association.
We also conducted meta-analyses in strata of 
menopausal status for both cancer sites, in strata of 
body mass index (BMI) and estrogen/progesterone (ER/
PR) receptor status for breast cancer, and in strata of 
histological type and severity of the neoplasm for ovarian 
cancer. Details on handling specific studies in the stratified 
analyses can be found in Supplementary Table 1. 
Sensitivity analyses were carried out by omitting one 
study at a time from the analyses and assessing its effect 
on the overall summary RRs as estimated before and after 
the exclusion of each study. 
A cumulative meta-analysis over year of publication 
was also performed for ovarian cancer.
The statistical analyses were conducted using Stata 
statistical software version 14.1 (StataCorp LP).
RESULTS
Breast cancer
Individual studies
In Table 1a the main characteristics of the 24 cohort 
and 18 case-control studies (including a total of 76,728 
breast cancer cases) considering a quantitative relation 
between coffee intake and breast cancer risk are shown. 
All studies were included in the overall meta-
analysis except the studies by Michels et al [48] 
and Bhoo Pathy et al [54], as the studies of 
Larsson et al [41] and of Bhoo Pathy et al [21], 
respectively, refer to/included the same cohorts, but 
were more informative. The former studies [48, 54] 
were, however, used in stratified analyses by BMI. Out 
of the indicated 22 cohort and 18 case-control studies, 
15 were conducted in North America, 18 in Europe 
and 7 in Asia. 
Figure 1 shows the overall RRs of breast cancer for 
the study-specific highest versus lowest coffee drinking 
categories, overall and by study design. The studies by 
Mannisto et al [66], Baker et al, [68], and Bhoo Pathy 
et al [21] were included twice in the meta-analysis as 
they reported RRs separately for pre- and post-menopausal 
women. Moreover, the article by Li et al [73] reported RRs 
from two case-control data sets, undertaken in Sweden 
and Germany (MARIE Study) and was also included twice 
in the meta-analysis.
All cohort and most case-control studies reported 
null associations. Only one small case-control study [71] 
reported a significantly increased risk (RR: 1.40, 95% CI, 
1.09-2.24). Two case-control studies [19, 28] reported 
significant inverse associations (RR: 0.60, 95%CI 0.20-
0.90, and RR: 0.71, 95%CI 0.51-0.98, respectively), 
while one additional study [68] reported an inverse 
association in pre-menopausal (RR: 0.62, 95%CI 0.39-
0.98) but not in post-menopausal women (RR: 0.99, 
95%CI 0.79-1.23)
Summary estimate
The summary RR of breast cancer risk for the highest 
versus lowest coffee consumption was indicative of a null 
association: overall: 0.97 (95% CI 0.93-1.00); cohort: 
0.98 (95% CI 0.94-1.02); case-control: 0.93 (95% CI 
0.86-1.01). No heterogeneity was found overall (I2 5.5 
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%); however, the heterogeneity was higher among case-
control studies (I2 34.2%) and null among cohort studies (I2 
approximately 0%). When the meta-analysis was confined 
to the 13 studies considering as the highest category of 
coffee consumption women drinking at least 4 cups/day 
(and with any type of reference category), the summary RR 
was of 0.94 (95% CI 0.86-1.03, p-heterogeneity 0.219, 
I2 21.6%). Additionally, among the 14 studies considering 
as the highest category of coffee consumption women 
drinking at least 3 cups/day (with reference category 
non-coffee drinkers), the summary RR was 0.98 (95% CI 
0.93-1.03, p-heterogeneity 0.305, I2 13.2%).
Caffeinated and decaffeinated coffee intake
 
Supplementary Figure 2 shows the forest plot of 
RRs of breast cancer corresponding to the highest 
versus lowest decaffeinated coffee intakes from the 
8 case-control and 5 cohort studies reporting such 
TABLE 1A. Main characteristics of the studies on breast cancer (BC) and ovarian cancer (OC) and coffee consumption included in 
the meta-analyses - Breast cancer
Study 
No
Study 
Reference Location
Enrollment/
follow-up
Cohort size 
(BC Cases) 
/ Cases/
controls
Cohort/
Program
Coffee 
categories 
(highest vs 
lowest)
Exposed 
cases3
Covariates controlled 
for in the Relative Risk 
estimate
Cohort 
studies
1
Snowdon 
and Phillips 
(1984)1[3]
USA 1960-1980/21 years
23,912 (men & 
women) (176)
White, Seventh-
day Adventists
Cups/day
>2/<1 26/131
Age, meat consumption, 
smoking
2 Jacobsen et al, (1986) [42] Norway
1967-69/11,5 
years 2,891 (32)
Two Norwegian 
cohorts
Cups/day
>7/<2 3/12 Age, sex and residence
3 Vatten et al. (1990) [43] Norway
1974-1977 
/12 years 14,593 (152)
National Health 
Screening 
Service for CVD
Cups/day
>7/<2 21/27 Age
4
Hoyer & 
Engholm (1992) 
[44] Denmark
1964-1986 
/4-26 years 5,207(51)
Glostrup 
Population 
Studies
Cups/day
>7/<2 NR
Not clear.  Possibly for social 
class, age at menarche, 
menopause status, number of 
full-term pregnancies, height, 
weight, BMI, alcohol and 
smoking, 
5
Folsom et al. 
(1993) [45] USA 1986/1990 34,388 (580)
Iowa Women’s 
Health Study 
Cups
≥4 per day/
never-<1/month
106/183
Age, waist/hip ratio, number of 
livebirths, age at first livebirth, 
age at menarche, family history 
of BC, as well as interactions 
of family history with waist/hip 
ratio, and number of livebirths
6
Stensvold and 
Jacobsen (1994) 
[46]
Norway 1977-1982/10 
years 21,238 (211)
Cardiovascular 
screening 
program
Cups/day 
≥7/≤ 2 43/22
Age, cigarettes per day and 
county of residence
7 Key at al, (1999) [47] Japan
1969-1970; 
1979-1980/ 
up to 1993
34,759 (427)
Radiation 
Effects Research 
Foundation’s Life 
Span Study
Times/week
>5/<1 122/151
Attained age, calendar period, 
city of residence, age at the 
time of the bombing and 
radiation dose
8
Michels et al. 
(2002)2[48]
 Sweden
1987-1990 
/9.5 years 59,036 (1271)
Swedish 
Mammography 
Screening 
Cohort
Cups/day 
≥4/≤1 214/76
Age, family history of BC, 
height, BMI, education, parity, 
age at first birth, alcohol 
consumption and total caloric 
intake
9 Suzuki et al. (2004) [49] Japan
Cohort 1: 
1984/9 years 
Cohort 2: 
1990/7 years
Cohort 1: 
14,409 (103) 
Cohort 2: 
20,595 (119)
Population-based 
prospective 
cohort study
Cups/day 
≥1/never NR
Age, types of health insurance, 
age at menarche, menopausal 
status, age at first birth, parity, 
mother’s history of BC, smoking, 
alcohol drinking and BMI
10 Hirvonen et al. (2006) [50] France
1994/6.6 
years 4396 (95)
Participants in 
the double blind 
clinical trial  
Supplementation 
en Vitamines 
et Mineraux 
Antioxydants 
Study (SU.
VI.MAX) 
ml/day: tertiles 
>253/≤111 33/30
Age, smoking, menopausal 
status, oral contraception use, 
family history of BC, number of 
children
BMI: body mass index; CVD: Cardiovascular diseases; HRT: hormone replacement therapy; H: hospital controls; P: population controls; 1: Breast 
cancer mortality; 2: Used only in stratified analysis; 3: Breast cancer cases in coffee categories contrasted in the RR estimate; 4 : This study was 
described as nested case–control in the original publication.  It was analysed as case-control, however, since the nested case-control design was not 
clearly described in the respective paper.
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information. The association was direct in one large 
case-control study [64] (RR: 1.20, 95%CI 1.03-1.39) 
and inverse in another one [40] (RR: 0.84, 95% CI 
0.72-0.98). The RRs from the remaining studies were 
not significantly different from unity. The summary RR 
was 1.00 (95% CI 0.93 to 1.08), with overall low 
between-study heterogeneity (p-heterogeneity 0.550, 
I2 32.2%).
Analysis of regular/caffeinated coffee intake 
indicated similar findings to the overall meta-analysis 
and was based on 11 studies with available 
information. The overall RR for the highest versus lowest 
reported coffee intake was 0.93 (95% CI 0.89, 0.97) 
(data not shown).
Subgroup analysis
Summary RRs (95% CI) of breast cancer risk for 
the highest versus the lowest coffee consumption in 
TABLE 1A (CONTINUED). Main characteristics of the studies on breast cancer (BC) and ovarian cancer (OC) and coffee 
consumption included in the meta-analyses - Breast cancer
Study 
No
Study 
Reference Location
Enrollment/
follow-up
Cohort size 
(BC Cases) 
/ Cases/
controls
Cohort/
Program
Coffee 
categories 
(highest vs 
lowest)
Exposed 
cases3
Covariates controlled 
for in the Relative Risk 
estimate
Cohort 
studies
11 Ganmaa et al. (2008) [51] USA
1976/ 1980-
2002
85,987 
(5,272)
Nurses Health 
Study (NHS) 
Cups
≥4 per 
day/<1/
month
637/837
Age, smoking status, BMI, 
physical activity, height, 
history of benign breast 
disease, family history of 
BC, weight change since 
age 18, age at menarche, 
parity, age at first birth, 
alcohol intake, total energy 
intake, age at menopause 
and postmenopausal 
hormone use
12 Ishitani et al. (2008) [52] USA
1992 /10 
years 
38,432 
(1188)
US health 
professionals: 
selection of 
participants in 
a randomised 
study
Cups
≥4 per day/ 
almost never
191/274
Age and randomized 
treatment, as well as, 
for: alcohol consumption, 
BMI, family history of BC, 
history of hysterectomy, 
bilateral oophorectomy, 
smoking status, history of 
benign breast disease, 
age at menarche, parity, 
age at first birth, physical 
activity, total energy intake, 
multivitamin use, age at 
menopause, menopausal 
status, and postmenopausal 
hormone use
13 Larsson et al. (2009) [41] Sweden
1987-1990 /
up to 2009
61,433 
(2,952)
Swedish 
Mammography 
Cohort
Cups/day 
>4 vs <1 492/251
Age, education, BMI, 
height, parity, age at first 
birth, age at menarche, 
age at menopause, use of 
oral contraceptives, use of 
postmenopausal hormones, 
family history of BC, and 
intakes of alcohol, tea and 
total energy
14 Wilson et al. (2009) [53] USA
1991/14 
years
90,628 
(1,179)
Nurses Health 
Study II (NHS II)
Quintiles of 
servings/day
5th/1st
258/270
Age, calendar year, BMI, 
height, oral contraceptive 
use, parity and age at first 
birth, age at menarche, 
family history of BC, history 
of benign breast disease, 
smoking, physical activity, 
animal fat, glycemic load, 
alcohol intake, and total 
energy intake
BMI: body mass index; CVD: Cardiovascular diseases; HRT: hormone replacement therapy; H: hospital controls; P: population controls; 1: Breast 
cancer mortality; 2: Used only in stratified analysis; 3: Breast cancer cases in coffee categories contrasted in the RR estimate; 4 : This study was 
described as nested case–control in the original publication.  It was analysed as case-control, however, since the nested case-control design was not 
clearly described in the respective paper.
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TABLE 1A (CONTINUED). Main characteristics of the studies on breast cancer (BC) and ovarian cancer (OC) and coffee 
consumption included in the meta-analyses - Breast cancer
Study 
No
Study 
Reference Location
Enrollment/
follow-up
Cohort size 
(BC Cases) 
/ Cases/
controls
Cohort/
Program
Coffee 
categories 
(highest vs 
lowest)
Exposed 
cases3
Covariates controlled 
for in the Relative Risk 
estimate
Cohort 
studies
15
Bhoo-
Pathy et al. 
(2010)2[54]
Netherlands
1993–
1997/9.6 
years
27,323 (681)
European 
Investigation 
into Cancer 
and nutrition 
(EPIC) 
-Netherlands
Cups/day 
>5/>0-1 151/110
Age at recruitment, smoking 
status, educational status, 
BMI, alcohol and energy 
intake, fat and fiber intake, 
tea intake, physical activity 
level, ever prior use of oral 
contraceptives, presence 
of hypercholesterolemia, 
cohort, family history of 
BC, age at menarche, and 
parity
16 Boggs et al. (2010) [55] USA
1995/ 12 
years
52,062 
(1268)
Black 
Women’s 
Health Study 
Cups/day
 >4/
never-<1/mo
49/592
Energy intake, age at 
menarche, BMI at age 
18, family history of BC, 
education, geographic 
region, parity, age at first 
birth, oral contraceptive 
use, menopausal status, 
age at menopause, 
menopausal hormone use, 
vigorous activity, smoking 
status, and alcohol, tea and 
decaffeinated coffee intakes
17 Iwasaki et al. (2010) [56] Japan
1990 (Cohort 
I); 1993 
(Cohort II) 
/2006
53,793 (581)
Japan Public 
Health 
Center-based 
Prospective 
Study 
Cups
≥3 per 
day/<1 per 
week
63/161
Age, area, age at 
menarche, menopausal 
status at baseline, 
age at menopause for 
postmenopausal women, 
number of births, age at 
first birth, height, BMI, 
alcohol intake among 
regular drinkers, smoking, 
leisure time physical activity, 
exogenous hormone use, 
family history of breast 
cancer, green tea, oolong 
tea, and black tea intakes
18 Nilsson et al. (2010) [57] Sweden
1992-2007 
/2007 32,178 (587)
Vasterbotten 
Intervention 
Project 
Occasions/
day 
≥4/<1
163/58
Sex, age, BMI, smoking, 
education, and recreational 
physical activity
19
Fagherazzi 
et al. (2011) 
[58]
France 1990/2005 67,703 (2,868)
Teachers, 
insured by the 
national health 
insurance 
system
Cups/day
 >3/non-
consumer
834/410
Age, baseline variables 
(total energy intake, ever 
use of oral contraceptives, 
age at menarche, age 
at menopause, number 
of children, age at first 
pregnancy, history of BC 
in the family and years 
of schooling) and time-
dependent variables (current 
use of postmenopausal 
hormone therapy (for 
postmenopausal women 
only), personal history of 
benign breast disease, 
menopausal status and BMI
BMI: body mass index; CVD: Cardiovascular diseases; HRT: hormone replacement therapy; H: hospital controls; P: population controls; 1: Breast 
cancer mortality; 2: Used only in stratified analysis; 3: Breast cancer cases in coffee categories contrasted in the RR estimate; 4 : This study was 
described as nested case–control in the original publication.  It was analysed as case-control, however, since the nested case-control design was not 
clearly described in the respective paper.
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strata of selected covariates are shown in Table 2. 
No significant heterogeneity was found by caffeine 
content, geographic area, menopausal status, BMI 
and, among case-controls studies, by type of controls. 
ER/PR breast cancer type was reported in 6 cohort 
studies [21, 23, 41, 55, 58, 59] for all or for a 
subgroup of participants only (13,346 cases). There 
was no evidence of heterogeneity across strata of ER/
PR. Within ER/PR strata, between-study heterogeneity 
was not statistically significant and medium to low, 
with the exception of RRs among the ER+/PR- subgroup 
(4 studies) for which heterogeneity was 70.4%.
Sensitivity analysis and publication bias
In sensitivity analysis, the summary RR of breast 
cancer in association to coffee intake (highest versus 
TABLE 1A (CONTINUED). Main characteristics of the studies on breast cancer (BC) and ovarian cancer (OC) and coffee 
consumption included in the meta-analyses - Breast cancer
Study 
No
Study 
Reference Location
Enrollment/
follow-up
Cohort size 
(BC Cases) 
/ Cases/
controls
Cohort/
Program
Coffee 
categories 
(highest vs 
lowest)
Exposed 
cases3
Covariates controlled 
for in the Relative Risk 
estimate
Cohort 
studies
20 Gierach et al. (2012) [59] USA
1995–1996 
/2006
198,404 
(9,915)
National 
Institutes of 
Health-AARP 
Diet and 
Health Study
Cups/day
>4/never 1217/1138
Age at entry, race/ethnicity, 
education, BMI, smoking 
status and dose, alcohol, 
proportion of total energy 
from fat, age at first live 
birth, menopausal hormone 
therapy (HT) use, history of 
breast biopsy, and family 
history of breast cancer in a 
first degree relative
21
Bhoo-Pathy 
et al. (2015) 
[21]
Europe 1992-2000 /2010
335,060 
(10,198)
European 
Investigation 
into Cancer 
and nutrition 
(EPIC)
ml/day
high/no 
intake
252/81
(pre-
menopausal)
1860/732 
(post-
menopausal)
Age at menarche, ever 
use of oral contraceptives, 
age at first delivery, ever 
breastfeeding, smoking 
status, education, physical 
activity, alcohol, height, 
weight, energy intake from 
fat and non-fat sources, 
total saturated fat and 
fiber intakes, tea intake, 
as well as, ever-use of 
postmenopausal hormones
22 Hashibe et al. (2015) [22] USA
1992, 2001 
/ 2011
50563 
(1703)
Prostate, Lung, 
Colorectal, 
and Ovarian 
cancer 
screening trial 
(PLCO) 
Cups/day
≥2/<1
1cup 
increment
828/599
Age, sex, race, education, 
cigarette pack-years, and 
alcohol drinking frequency
23 Oh et al. (2015) [23] Sweden
1991-1992 
/2012
42,099 
(1395)
Women’s 
Lifestyle and 
Health
Cups/day
>5/0
1cup/day 
increment
421/99
Age, BMI, duration of 
breastfeeding, and alcohol 
consumption, as well as, 
smoking status, education, 
and physical activity (in 
sensitivity analyses)
24 Lukic et al. (2016) [25] Norway
1991-1992, 
1996-1997, 
2003,2004 
/1996-2013
91,767 
(3,277)
The 
Norwegian 
Women and 
Cancer
Cups/day 
>7 vs ≤1 182/626
Menopausal status, smoking 
status, education, BMI, 
physical activity level, 
alcohol consumption, 
number of children age at 
first birth, use of hormone 
replacement therapy, and 
maternal history of breast 
cancer – repeated measures 
for these factors, as well as, 
for coffee intake were also 
taken considered
BMI: body mass index; CVD: Cardiovascular diseases; HRT: hormone replacement therapy; H: hospital controls; P: population controls; 1: Breast 
cancer mortality; 2: Used only in stratified analysis; 3: Breast cancer cases in coffee categories contrasted in the RR estimate; 4 : This study was 
described as nested case–control in the original publication.  It was analysed as case-control, however, since the nested case-control design was not 
clearly described in the respective paper.
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TABLE 1A (CONTINUED). Main characteristics of the studies on breast cancer (BC) and ovarian cancer (OC) and coffee 
consumption included in the meta-analyses - Breast cancer
Study 
No
Study 
Reference Location
Enrollment/
follow-up
Cohort size 
(BC Cases) 
/ Cases/
controls
Cohort/
Program
Coffee 
categories 
(highest vs 
lowest)
Exposed 
cases3
Covariates controlled 
for in the Relative Risk 
estimate
Cohort 
studies
1 Lubin et al. (1985) [28] Israel 1975 -1979 807/807 P
Cups/day
>4/0 155/141
Age, country of origin, 
length of residence in Israel.
2
Rosenberg et 
al. (1985) 
[60]
USA 1975-1982
2,651 
/1501 H 
(non cancer 
controls)
Cups/day
>5/0 413/493
Age, race, religion, 
cigarette smoking, age 
at menarche, age at first 
pregnancy, parity, type 
of menopause, age at 
menopause, history of 
fibrocystic breast disease, 
family history of BC (in the 
mother or sister(s)), BMI, 
years of education, tea 
and alcohol consumption, 
location of the hospital, 
year of interview, and 
number of previous non-
obstetric hospitalizations
3
Katsouyanni 
et al. (1986) 
[61]
Greece 1983–1984 120 /120 H
Tertiles of 
frequency of 
use 
3rd/1st
24/29 No adjustment
4 Schairer et al. (1987) [62] USA 1977-1980
1510 /1882 
P
Breast Cancer 
Detection 
Demonstration 
Project 
(screening 
project) 
Cups/day 
(brewed 
coffee)
>5/0
194/171
No adjustment, but 
matching for age, center, 
screening program entry 
and duration
5
Ewertz and 
Gill (1990) 
[63]
Denmark 1983-1984 1474 /1322 P
Cups/day
>10/<3 82/358
Age at diagnosis and place 
of residence
6
McLaughlin 
et al. (1992) 
[64]
USA 1982-1984 1617 /1617 P
Drinkers/non 
drinkers 1463/154
Age, county of residence, 
race, menstrual status, age 
at first live birth, history 
of  benine breast disease, 
family history of breast 
cancer and alcohol intake
7 Levi et al. (1993) [65] Switzerland 1992 107 /318 H
Tertiles of 
frequency of 
use 
3rd/1st
33/32 Age
8 Tavani et al. (1998) [40] Italy
1983-1991 
and 1991-
1994
5,984 
/5,504 H
Cups/day
>4/0 784/812
Study/centre, age, 
education, BMI, smoking 
status, total alcohol intake, 
age at menarche and 
menopause, parity and 
age at first birth, use of oral 
contraceptives, use of HRT, 
history of benign breast 
disease and family history 
of breast cancer.
9
Mannisto et 
al. (1999) 
[66]
Finland 1990-1995 310/454 P
Quintiles of 
g/day
>488/<120 
(pre-
menopausal)
>488/<240 
(post-
menopausal)
NR
Age, area (rural/urban),
age at menarche, age at 
first full-term pregnancy, use 
of oral contraceptives, use 
of estrogen replacement 
therapy, first-degree family 
history of breast cancer, 
history of benign breast 
disease, level of education, 
current alcohol intake, 
smoking habits, leisure 
activity and waist-to-hip 
ratio.
BMI: body mass index; CVD: Cardiovascular diseases; HRT: hormone replacement therapy; H: hospital controls; P: population controls; 1: Breast 
cancer mortality; 2: Used only in stratified analysis; 3: Breast cancer cases in coffee categories contrasted in the RR estimate; 4 : This study was 
described as nested case–control in the original publication.  It was analysed as case-control, however, since the nested case-control design was not 
clearly described in the respective paper.
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lowest intake) did not change appreciably when each 
study was excluded in turn and the RR was estimated 
from the remaining studies (RRs range: 0.96 to 0.97, not 
significant in all analyses). The funnel plot of individual RRs 
for breast cancer studies is shown in Supplementary Figure 
3. There was no indication for publication bias for studies 
investigating the association of coffee intake with breast 
cancer risk (p-values of Egger’s and Begg’s test: 0.877 
and 0.753, respectively).
Ovarian cancer
Individual studies
Table 1b shows the main characteristics of the 13 
TABLE 1A (CONTINUED). Main characteristics of the studies on breast cancer (BC) and ovarian cancer (OC) and coffee 
consumption included in the meta-analyses - Breast cancer
Study 
No
Study 
Reference Location
Enrollment/
follow-up
Cohort size 
(BC Cases) 
/ Cases/
controls
Cohort/
Program
Coffee 
categories 
(highest vs 
lowest)
Exposed 
cases3
Covariates controlled 
for in the Relative Risk 
estimate
Cohort 
studies
10 Wu et al. (2003) [67]
USA (Asian 
population) 1995 -1998 501 /594 P
Los Angeles 
County Cancer 
Surveillance 
Program 
ml/day
>240/0 152/135
Education, age at 
menarche, pregnancy, 
current BMI, total caloric 
intake, menopausal status 
and use of menopausal 
hormones intake of soy, 
dark green vegetables 
smoking history, alcohol 
intake, physical activity, and 
family history of BC
11 Baker et al. (2006) [68] USA 1982-1988
1932 /1895 
H
Cups/day
>4/<1
57/136 
(pre-
menopausal)
261/462 
(post-
menopausal)
Age, residence, and age at 
birth of first child
12 Hirose et al. (2007) [69] Japan 1990-2000
2122 
/12,425 H
Hospital-based 
Epidemiological 
Research 
Program at Aichi 
Cancer Center 
(HERPACC)
Cups/day
>3/0 254/448
Age, year, motivation for 
consultation, parity, age 
at first delivery, smoking, 
drinking, exercise and BMI, 
as well as for a number of 
dietary variables
13 Zhang et al, (2007) [70] China 2004 - 2005
1009 /1009 
H Yes/no 98/120 No adjustment 
14
Bissonauth et 
al. (2009)4 
[71] 
Canada 2004-2006 280 /280 P Cups/day>8/≤2 88/102
Age, education, physical 
activity, smoking, coffee 
consumption and total 
energy intake
15 Rabstein et al. (2010) [72] Germany 2000-2004
1020 /1047 
P
Gene-
ENvironment 
Interaction and 
breast CAncer 
(GENICA)
Cups/day
≥4/0 379/145
Age, breast cancer in 
mother or sister, HRT, 
number of
mammograms, physical 
activity, lifetime 
breastfeeding
16 Li et al. (2011) [73]
Sweden 
Germany 
1993-1995
2002-2005
2818 /3111 
P
2651 /5395 
P
Swedish Study
Mamma 
Carcinoma 
Risk factor 
Investigation 
(MARIE) Study
Cups/day
>5/≤1
328/298
157/287
Age at enrolment, HRT, 
smoking, education and 
daily alcohol consumption
17 Lowcock et al. (2013) [19] Canada 2002, 2003
3,062 
/3,427 P
Cups/day
>5/never 71/540
age, smoking status, 
ethnicity and level of 
strenuous physical activity 
as a teenager
18 Mizoo et al. (2013) [20] Japan 2010 -2011 472 /464 P
Times/week
≥4/<1 45/132 Age
BMI: body mass index; CVD: Cardiovascular diseases; HRT: hormone replacement therapy; H: hospital controls; P: population controls; 1: Breast 
cancer mortality; 2: Used only in stratified analysis; 3: Breast cancer cases in coffee categories contrasted in the RR estimate; 4 : This study was 
described as nested case–control in the original publication.  It was analysed as case-control, however, since the nested case-control design was not 
clearly described in the respective paper.
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TABLE 1B. Main characteristics of the studies on breast cancer (BC) and ovarian cancer (OC) and coffee consumption included in 
the meta-analyses - Ovarian cancer
Study 
No
Study 
reference Location
Enrollment/
follow-up
Cohort size 
(OC cases) 
/ Cases/
controls
Cohort/
Program
Coffee 
categories 
(highest vs 
lowest)
Exposed 
cases3
Covariates controlled 
for in the Relative Risk 
estimate
Cohort 
studies
1
Snowdon 
and Phillips 
(1984)1[3]
USA
1960-
1980/21  
years
23,912 (men 
and women) 
(51)
Seventh-day 
Adventists
Cups/day
>2/<1 10/35
Age, meat consumption, 
smoking
2 Jacobsen et a (1986) [42] Norway
1967-
69/11,5  
years
2,891 (12) Two Norwegian cohorts
Cups/day
>7/<2 1/5 Age and residence
3
Stensvold 
and Jacobsen 
(1994) [46]
Norway
1977-
1982/10  
years
21,238 (93)
Cardiovascular 
screening 
program
Cups/day 
≥7/≤ 2 18/5
Age, cigarettes per day 
and county of residence
4
Larsson and 
Wolk (2005) 
[74]
Sweden 1987-1990/ 15,1 years
61,057 
(301)
Swedish 
Mammography 
Screening 
Cohort
Cups/day
≥4/<1 49/24
Age, BMI, education, 
parity, use of oral 
contraceptives, total energy 
intake, fruits, intake of 
vegetables, milk, tea
5 Silvera et al. (2007) [75] Canada
1980-1985/ 
16,4 years
48,776 
(264)
Canadian 
Cancer Breast 
Screening Study 
(NBSS)
Cups/day
≥4/0 41/34
Age, smoking, alcohol 
consumption, education, 
BMI, parity, physical 
activity, menopause,  use 
of oral contraceptives, total 
energy intake, lactose, 
study center, randomization 
group
6
Steevens et 
al. (2007) 
[17]
The 
Netherlands
1986-1999/ 
13,3 years 2,083 (280)
Netherlands 
Cohort Study
Cups/day
≥5/<1 59/15
Age,  use of oral 
contraceptives, parity, 
smoking, tea
7
Lueth et al. 
(2008) [76] USA 1986/ 16 years
29,060 
(266)2
Iowa Women’s 
Health Study
(IWH)
Cups/day
≥5/0 40/24
Age, smoking, BMI, age 
at menopause, parity,  use 
of oral contraceptives, 
education, physical activity, 
total energy intake
8
Tworoger et 
al. (2008) 
[77] USA
1976-1980/ 
24 years
80,253 
(507)
Nurses’ Health 
Study (NHS)
Cups/day 
(Caffeinated 
coffee)
≥3/0
97/78
Age, parity,  use of oral 
contraceptives, HRT, tubal 
ligation, smoking, BMI
9
Kotsopoulos 
et al. (2009) 
[78] USA 1976-2004
234 
cases/691 
controls 
(nested case-
control study)
Nurses’ Health 
Study (NHS);  
Nurses’ Health 
Study II (NHS II)
Cups/day
≥2.5/<2/5 66/151
Age, parity,  use of oral 
contraceptives, HRT, tubal 
ligation, smoking, BMI, 
family history of breast/
ovarian cancer
10
Nilsson et al. 
(2010) [57] Sweden 1985-1994/ 6 years 32,178 (71)
Vasterbotten 
Intervention 
Project
Occasions/
day
≥4/<1
25/5 Age, BMI, education, physical activity, smoking
11
Braem et al. 
(2012) [18] Europe
1992-
2000/11.7 
years
330,849 
(1244)
European 
Prospective 
Investigation 
into Cancer and 
nutrition (EPIC)
ml/day
5th quintile/
no-consumers
189/84
Age, parity,  use of 
oral contraceptives, 
BMI, smoking, alcohol 
consumption, total energy 
intake, breastfeeding, 
menopause, height, 
education
12
Hashibe et 
al. (2015) 
[22]
USA 1992-2001/ 10-13 years
50,563 
(162)
Prostate, Lung, 
Colorectal, and 
Ovarian Cancer 
Screening Trial 
(PLCO)
Cups/day
≥2/<1
1 cup/day 
increment
82/50
Age, race, education, 
smoking, alcohol 
consumption
13 Lukic et al. (2016) [25] Norway
1991-
2004/1996-
2013
91,797 
(446)
Norwegian 
Women and 
Cancer Study
Cups/day
>7/<1 NR
Age, menopause, smoking, 
education, parity,  use of 
oral contraceptives, HRT, 
maternal history of breast 
cancer
BMI: body mass index; CVD: Cardiovascular diseases; HRT: hormone replacement therapy; H: hospital controls; P: population controls; 1: Ovarian 
cancer mortality; 2: Used only in stratified analysis by histological type of ovarian cancer 3:Contrasted in the RR estimation 
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TABLE 1B (CONTINUED). Main characteristics of the studies on breast cancer (BC) and ovarian cancer (OC) and coffee consumption 
included in the meta-analyses - Ovarian cancer
Study 
No Study reference Location
Enrollment/
follow-up
Cohort size 
(OC cases) 
/ Cases/
controls
Cohort/
Program
Coffee 
categories 
(highest vs 
lowest)
Exposed 
cases3
Covariates controlled 
for in the Relative Risk 
estimate
Case Control 
studies
1 Hartge et al. (1982) [2] USA NR 158 /187H
Cups/day: 
≥4/0 38/39 Age, parity, smoking
2 Byers et al. (1983) [79] USA 1957-1965
274 /1034 
H
Cups/day: 
≥3/0 126/52 Age, parity, smoking
3 Cramer et al. (1984) [80] USA 1978-1981 215 /215 P
Cups/day: 
≥5/<0 36/28 Age, parity
4 Tzonou et al. (1984) [39] Greece 1980-1981 150 /250 H
Cups/day
≥3.5/0 11/26
Age, parity, age at 
menopause, smoking, 
alcohol consumption, 
estrogen use
5 La Vecchia et al (1984) [15] Italy 1979-1983 247 /494 H
Cups/day
≥4/0 39/74
Education, age, parity, 
age at first birth, use of 
oral contraceptives, age at 
menopause, BMI, smoking, 
alcohol consumption
6 Miller et al. (1987) [81] USA 1976-1983
290 /580 H 
(non-cancer 
controls)
Cups/day
≥5/0 36/92
Age, race, religion, 
smoking, alcohol 
consumption, use of oral 
contraceptives, conjugated 
estrogen use, BMI, age 
at menarche, age at 
first pregnancy, age 
at menopause, type of 
menopause, education, 
geographical location of 
hospital, year of interview, 
number of non obstetric 
hospital admissions
7 Mori et al. (1988) [82] Japan
1980-1981, 
1985-1986 110 /110 P
Daily /
non-daily 
consumption
46/64
Age, year of interview, 
smoking, BMI, alcohol 
consumption, milk, meat, 
fish
8 Whittemore et al. (1988) [16] USA 1983-1985 280 /259 P
Cups/day17 
≥4/0 54/11 Age, race, year of interview, hospital, smoking
9 Polychronopoulou et al. (1993) [83] Greece 1989-1991 189/200 P
Cups/day
>2/never 93/18 Age
10 Kuper et al. (2000)2 [84] USA 1992-1997 549 /516 P
New England 
Case-Control 
Study (NECC)
Cups/day
>4/never 61/128
Age, center, parity, BMI, 
oral contraceptives, , family 
history of breast/ovarian/
prostate cancer, tubal 
ligation, education, alcohol 
consumption, smoking, 
marital status
11 Tavani et al. (2001) [85] Italy 1992-1999
1031 
/2411 H
Cups/day 
>4/<1 155/188
Age, study center, year 
of interview, education, 
parity, age at menopause, 
oral contraceptives use, 
BMI, total energy intake, 
family history of ovarian/
breast cancer
BMI: body mass index; CVD: Cardiovascular diseases; HRT: hormone replacement therapy; H: hospital controls; P: population controls; 1: Ovarian 
cancer mortality; 2: Used only in stratified analysis by histological type of ovarian cancer 3:Contrasted in the RR estimation 
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cohort and 19 case-control studies (including a total of 
13,111 ovarian cancer cases) considering a quantitative 
relation between coffee intake and ovarian cancer risk. 
All studies were included in the overall meta-analysis 
except for the study by Kuper et al [84], as the study of 
Kotsopoulos et al [78] included the same case-control 
dataset, but was more informative. The study by Kuper et al 
[84] was, however, included in stratified analyses by BMI. 
From the indicated 13 cohort and 18 case-control 
studies included in the overall meta-analysis 14 were 
conducted in North America, 13 in Europe, 3 in Asia and 
1 in Australia. 
The RRs for ovarian cancer comparing the highest 
with the lowest coffee intake are shown in Figure 2. The 
study by Kotsopoulos et al [78] was included twice in the 
meta-analysis – one as a cohort and one as a case-control 
study, because it included the pooled estimates from the 
Nurses’ Health Study and the Nurses’ Health Study II 
(cohort studies) and the estimate of the NEEC study (a 
case-control study). 
Cohort studies revealed no relation. Among case-
control studies, one [15] reported a significantly increased 
risk (RR: 2.20, 95% CI 1.20-3.90), and two studies [86, 
88] reported inverse associations (RR: 0.66, 95% CI 0.47-
0.93, and, RR: 0.62, 95% CI 0.41-0.95, respectively). 
Summary estimate
The summary RR for all studies was 1.03 (95% 
CI 0.93–1.14); 1.03 (95% CI 0.89 to 1.19) among 
case-control, and 1.03 (95% CI 0.90, 1.18) among 
TABLE 1B (CONTINUED). Main characteristics of the studies on breast cancer (BC) and ovarian cancer (OC) and coffee consumption 
included in the meta-analyses - Ovarian cancer
Study 
No
Study 
reference Location
Enrollment/
follow-up
Cohort size 
(OC cases) 
/ Cases/
controls
Cohort/
Program
Coffee 
categories 
(highest vs 
lowest)
Exposed 
cases3
Covariates controlled 
for in the Relative Risk 
estimate
13
Goodman et 
al. (2003) 
[87]
 
Hawaii 1993-1999 164 /194 P
Cups/day
>1/non-
drinkers 64/32
Age, race, use of oral 
contraceptives, tubal 
ligation
14 Jordan et al. (2004) [88] Australia 1990-1993 696 /786 P
Cups/day
>4/non-
drinkers
86/127
Age, BMI, use of oral 
contraceptives, parity, 
smoking, alcohol 
consumption, education, 
energy intake
15
Riman et al. 
(2004) [89] Sweden 1993-1995 655 /3899 P
Cups/day 
>6/non-
drinkers
61/33
Age, parity, BMI, age at 
menopause, use of oral 
contraceptives, HRT
16 Baker et al. (2007) [90] USA 1982-1998 414 /868 H
Cups/day
>4/non-
drinkers
66/139 Age, residence, year of interview
17 Hirose et al. (2007) [69] Japan 1990-2000
166 /3224 
H
Cups/day:
>3/non-
drinkers
20/35
Age, year of interview, 
motivation of consultation, 
parity, age at first 
birth, smoking, alcohol 
consumption, physical 
activity, BMI, various 
dietary items
18 Song et al. (2008) [91] USA 2002-2005
781 /1263 
P
Cups/day:
>3/non-
drinkers
123/216
Age, county, year of 
diagnosis, race, parity, 
duration of use of oral 
contraceptives, BMI, 
smoking, tubal ligation/
hysterectomy, family history 
of breast/ovarian cancer
Kotsopoulos 
et al. (2009) 
[78]
USA
1992-1997 
and 1998-
2003
1120/1160 
P
New England 
Case-Control 
Study (NECC)
Cups/day:
>2.5/<2.5 400/645
Age, parity, use of oral 
contraceptives, HRT, tubal 
ligation, family history of 
breast/ovarian cancer, 
BMI, smoking
19
Gosvig et al. 
(2015) [24] Denmark 1995-1999 382 /911 P
Cups/day:
>4/none 109/27 Age, parity, use of oral contraceptives
BMI: body mass index; CVD: Cardiovascular diseases; HRT: hormone replacement therapy; H: hospital controls; P: population controls; 1: Ovarian 
cancer mortality; 2: Used only in stratified analysis by histological type of ovarian cancer 3:Contrasted in the RR estimation 
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cohort studies. Overall between-study heterogeneity was 
moderate (I2 31.9 %), higher among case-control (I2 
44.3%) than among cohort (I2 8.9%) studies. When 
the analysis included only the 13 studies considering 
as the highest category of coffee consumption women 
drinking at least 4 cups/day (with any type of reference 
category), the summary RR was 0.99 (95% CI 0.83-
1.17, p-heterogeneity 0.155, I2=28.8%). In addition, 
when only the 15 studies having as highest category of 
consumption at least 3cups/day (with reference category 
non-coffee drinkers) were analyzed, the summary RR was 
of 1.11 (95% CI 0.92-1.34, p-heterogeneity 0.025, I2 
46.5%). 
Caffeinated/decaffeinated coffee intake
Five case-control and 4 cohort studies reported 
associations between decaffeinated coffee intake and 
ovarian cancer risk. Supplementary Figure 4 shows the 
forest plot of the RRs for the highest versus the lowest 
decaffeinated coffee intakes. The RR tended to be below 
unity in all studies, with significant inverse associations 
in two studies [85, 90] (RR: 0.64, 95%CI 0.42-0.96, 
and RR: 0.71, 95%CI 0.51-0.9, respectively). Only 
one study [87] had a RR above unity (RR=1.10, non-
statistically significant). The overall association was inverse 
and significant (RR 0.83 (95% CI 0.71 to 0.96), I2 
approximately 0). Information on caffeinated coffee was 
available in 6 studies. The overall RR for the association 
FIGURE 1. Relative risks (RRs) and 95% confidence intervals (CI) of breast cancer for the highest versus the lowest coffee drinking 
category from case-control and cohort studies, and from all the studies combined. The combined RRs and 95% CI were calculated 
using the random-effects models.
e13078-13
ORIGINAL ARTICLESEpidemiology Biostatistics and Public Health - 2019, Volume 16, Number 1
Coffee, breast and ovarian cancer
of caffeinated coffee (highest vs lowest intake) with 
ovarian cancer risk was 1.08 (95%CI 0.84-1.38) with 
moderate-to-high between study heterogeneity (I2 =62.4%, 
p-heterogeneity, 0.021) (data not shown).
Subgroup analysis
In Table 3 summary RRs (95% CI) of ovarian cancer 
comparing the highest versus the lowest coffee consumption 
are shown by strata of selected covariates. No significant 
TABLE 2. Summary relative risks (RRs) and 95% confidence intervals (CI) of breast cancer for the highest versus the lowest coffee 
drinking category in strata of selected covariates. 
N studies RR (95% CI) P-heterogeneityamong studies I
2
Type of coffee
Caffeinated 11 0.93 (0.89-0.97) 0.295 16.6%
Decaffeinated 13 1.00 (0.93-1.08) 0.550 0.0%
P-heterogeneitya=0.099
Geographic area
North America 15 0.97 (0.92-1.02) 0.285 14.7%
Asiab 7 0.98 (0.85-1.14) 0.177 32.9%
Europe 18 0.96 (0.91-1.01) 0.552 0%
Northern Europec 12 0.94 (0.85-1.02) 0.241 19.5%
Southern Europec 5 0.99 (0.91-1.09) 0.949 0%
P-heterogeneitya,d=0.943
Menopausal statuse
Pre-menopause 13 0.99 (0.90-1.08) 0.395 5.1%
Post-menopause 16 0.94 (0.89-1.00) 0.152 26.4%
P-heterogeneitya=0.376
Body mass indexf
Normo weight 6 0.94 (0.85-1.04) 0.502 0.0%
Overweight 6 1.00 (0.89-1.13) 0.452 0.0%
P-heterogeneitya=0.438
Receptor status
ER+/PR+ 6 1.00 (0.92-1.08) 0.691 0.0%
ER+/PR- 4 0.85 (0.61-1.19) 0.018 70.4%
ER-/PR+ 3 0.69 (0.44-1.07) 0.800 0.0%
ER-/PR- 6 0.90 (0.78-1.04) 0.913 0.0%
P-heterogeneitya=0.222
Type of controlsg
Hospital based 7 0.96 (0.87-1.06) 0.041 44.7%
Population based 11 0.91 (0.81-1.04) 0.318 14.3%
P-heterogeneitya=0.510
a Among strata; b Including one study from Israel [28]; c One study conducted within the European Prospective Investigation into Cancer and Nutrition 
cohort [21], which included participants from 10 European countries, was not considered in the stratified analysis by European location. d p value 
comparing summary estimates across studies from North America, Asia, and Europe. e This analysis included estimates from a study in which age 
at breast cancer (<49 years versus >55 years) was considered a proxy of menopausal status [57]. Estimates from a cohort in which over 96% of 
women were postmenopausal at baseline [59] and from a cohort of women ≥55 years of age at baseline [22] were included in the stratum of post-
menopausal breast cancer. f Normo-weight / overweight subjects were defined, respectively, as follow: body mass index (BMI) <25 / ≥25 kg/m2 in 2 
studies [51-52], BMI≤25 / >25 kg/m2 in 2 studies [48,54], BMI<24 / ≥24 kg/m2 in one study [43], and BMI≤26.5 / >26.5 kg/m2 in one study 
[40]. g Only for case-control studies; Studies using neighborhood controls as well as family-based controls were considered together with those using 
population-based controls.
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heterogeneity was found by caffeine content, geographic 
area and menopausal status. 
Histological type of the neoplasm (serous/mucinous/
endometrioid/clear cell) or severity of disease (invasive/
borderline) was reported in 7 studies [17, 24, 74, 84, 
88-90]. There was no evidence of heterogeneity across 
strata of either tumour characteristic. 
There was a significantly increased risk among 
hospital-based, case-control studies (RR: 1.18, 95%CI 
1.00-1.39) and among studies published before the 
year 2000 (RR: 1.37, 95%CI 1.12-1.69), while no 
association was observed among population-based case-
control studies (RR: 0.95, 95%CI 0.78-1.17) or among 
more recent studies (RR: 0.96, 95%CI 0.86-1.06). There 
was evidence for heterogeneity according to year of 
publication (p-heterogeneity, 0.003).
Figure 3 shows the cumulative meta-analysis for 
ovarian cancer for the highest versus the lowest coffee 
intake by year of publication. The cumulative RR for papers 
published up to 2000 was significantly above unity (RR: 
1.37, 95%CI 1.12-1.69), while it levelled down to unity 
afterwards. 
Sensitivity analysis and publication bias
The influence analyses did not reveal any notable change in 
the summary estimate with the exclusion in turn of any study, with 
summary RRs varying between 1.01 and 1.05 (not significant). 
The funnel plot of RRs for ovarian cancer studies is 
FIGURE 2. Relative risks (RRs) and 95% confidence intervals (CI) of ovarian cancer for the highest versus the lowest coffee drinking 
category from case-control and cohort studies, and from all the studies combined. The combined RRs and 95% CI were calculated 
using the random-effects models.
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shown in Supplementary Figure 5. P-values for Begg’s 
and Egger’s tests were both 0.008, indicating a potential 
for publication bias owned to the inclusion of published 
studies with rather imprecise positive associations of coffee 
intake with ovarian cancer risk (published before 2000) 
and the lack of similar studies showing inverse associations 
(lower left part of the funnel is missing in contrast to the 
lower right part of the funnel). 
DISCUSSION
In the present meta-analyses of all published data up 
to June 2016, including 41 studies and 76,728 breast 
cancer cases, and 32 studies and 13,111 ovarian cancer 
cases, we found no overall association between coffee 
consumption and breast or ovarian cancer risk. For both 
cancer sites, results were consistent among case–control 
and cohort studies, across different geographical areas, 
and for pre- and post-menopausal women. For breast 
cancer, summary estimates were also consistent in strata by 
BMI, receptor status, as well as among case-control studies 
with hospital-based or population-based control subjects. 
For ovarian cancer the null association with coffee intake 
was also consistent in strata defined by severity and 
histologic type of disease. 
Our findings are in agreement with reports of 
international research bodies [7]. The recent WCRF 
reports [4, 5] were based on analyses of cohort studies 
only, published up to 2016 and 2012 for breast and 
ovarian cancers respectively, and their evaluation of the 
evidence for coffee intake in relation to both cancers was 
“limited-no conclusion”. In our study we have analysed 
also all case-control studies published up to mid-2016 and 
we added three new cohort studies. Our results based on 
all available evidence up to June 2016, agree, further 
supplement and more precisely quantify those produced 
by the WCRF.
Our findings are also in agreement with recently 
published meta-analyses. For breast cancer previous 
meta-analyses including case-control and cohort studies 
[10, 12, 13] or cohort studies only [11, 14] had a few 
methodological limitations in the inclusion/exclusion of 
studies and eventually reported, not statistically significant 
weak inverse associations for the highest vs lowest coffee 
intake (RRs of around 0.95 overall) [10, 12, 13]. For 
ovarian cancer, previous meta-analyses using either cohort 
and case-control studies [17], or, cohort studies only 
[14,18] reported summary RRs close to unity similarly to 
our overall pooled estimate. Pooling RRs from case-control 
studies published up to 2007 resulted in a RR of 1.15 
(95% CI 0.89, 1.47) [17] whereas our pooled estimate 
including three additional case-control studies published 
after 2007 [24, 78, 91] was close to unity. None of the 
cohort studies found a statistically significant relation in ours 
and in previous meta-analyses [14, 17, 18]. 
We observed a weak positive association of ovarian 
cancer risk with increased coffee consumption among the 
12 studies (including only 3 prospective investigations) 
published before 2000, as well as among case–control 
studies with hospital-control patients, mostly published 
before 2000. This apparent inconsistency with the overall 
null association, may be due to false-positive results 
documented in earlier studies, as well as, selection bias 
associated with the hospital-based case-control design. 
Moreover, the significant p values from Begg’s and 
Egger’s tests indicated publication bias, probably due to 
the inclusion of older studies (published before 2000). 
According to this type of publication bias, however, the RR 
estimated from our meta-analysis is likely an overestimation 
of the “true” association of coffee intake with ovarian 
cancer risk and, therefore, our results further support the 
absence of such a relation. 
We also performed meta-analyses for decaffeinated 
coffee intake. For breast cancer we found a null overall 
association in agreement with results of the only meta-
analysis which investigated this relation [13]. For ovarian 
cancer the pooled RR was indicative of an inverse overall 
association (RR=0.83, 95% CI 0.71-0.96), but with 
no statistically significant heterogeneity across strata by 
caffeine content. Two of the 9 studies included in this 
meta-analysis [85, 90] showed decreased risk with 
increased decaffeinated coffee consumption, whereas the 
seven additional studies reported null associations. No 
previous meta-analysis of ovarian cancer has investigated 
this relation.
Coffee contains many bioactive compounds such 
as phenolic acids with strong antioxidant properties 
and cafestol and kahweol with anticarcinogenic activity 
[98] and, inverse association of this beverage with liver 
and endometrial cancer risk has been demonstrated [8, 
99]. Moreover, previous studies suggested that coffee 
and caffeine are inversely associated with sex hormones 
(testosterone and estradiol) [100, 101], higher levels 
of which may be associated with increased breast and 
ovarian cancer risk [102-104]. On the other hand coffee 
contains also acrylamide which has been suggested 
to increase breast and ovarian cancer risk [105]. The 
results of our meta-analysis demonstrating no association 
between the consumption of coffee and risk of breast or 
ovarian cancer may reflect a combination of positive and 
negative effects. 
In our meta-analysis, we pooled RRs for the highest 
versus the lowest coffee drinking categories based on the 
study-specific cut-offs and therefore the “exposed” category 
(highest consumption) varied across studies. Nevertheless, 
this approach has been adopted by previous meta-
analyses of coffee and various outcomes. We did not 
perform a dose-response meta-analysis since the null 
associations were consistent in overall and subgroup 
analyses. Our findings showed no material differences 
across different geographical locations with distinctly 
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TABLE 3. Summary relative risks (RRs) and 95% confidence intervals (CI) of ovarian cancer for the highest versus the lowest coffee 
drinking category in strata of selected covariates.
N studies RR (95% CI) P-heterogeneityamong studies I
2
Type of coffee
Caffeinated 6 1.08 (0.84-1.38) 0.021 62.4%
Decaffeinated 9 0.83 (0.71-0.96) 0.826 0.0%
P-heterogeneitya=0.076
Geographic area
North Americab 14 1.06 (0.94-1.20) 0.236 19.5%
Asia 3 1.02 (0.59-1.76) 0.034 70.3%
Europec 13 1.04 (0.89-1.22) 0.273 16.9%
Northern Europe 8 0.96 (0.79-1.16) 0.496 0.0%
Southern Europe 4 1.29 (0.83-2.02) 0.076 56.3%
Australia 1 0.62 (0.41-0.95) - -
P-heterogeneitya,d=0.121
Menopausal status
Pre-menopause 3 1.08 (0.67-1.73) 0.116 49.3%
Post-menopause 6 0.94 (0.72-1.22) 0.018 60.9%
P-heterogeneitya=0.604
Severity of cancer
Invasivee 7 0.95 (0.72-1.27) 0.008 65.4%
Borderline 3 1.07 (0.67-1.73) 0.731 0.0%
P-heterogeneitya=0.673
Histologic typef
Serous 6 0.90 (0.61-1.32) 0.019 63.0%
Mucinous 4 1.21 (0.64-2.31) 0.532 0.0%
Endometrioid 3 1.08 (0.63-1.84) 0.652 0.0%
Clear cell 2 1.44 (0.63-3.29) 0.292 9.9%
P-heterogeneitya=0.713
Type of controlsg
Hospital based 11 1.18 (1.00-1.39) 0.404 4.1%
Population based 8 0.95 (0.78-1.17) 0.066 47.2%
P-heterogeneitya=0.224
Year of study publication
<2000 12 1.37 (1.12-1.69) 0.672 0.0%
>=2000 19 0.96 (0.86-1.06) 0.106 29.5%
P-heterogeneitya=0.003
a Among strata; b Including one study from Hawaii [87]. c One study conducted within the European Prospective Investigation into Cancer and Nutrition 
cohort [21], which included participants from 10 European countries, was not considered in the stratified analysis by European location. d p value 
comparing summary estimates across studies from North America, Asia, Europe and Australia. e For one study we pooled RR for invasive serous, 
mucinous, endometrioid and clear cell type to obtain the RR for all invasive ovarian cancers [90]. f Invasive cancer only. g Only for case-control studies. 
One study including hospital and population controls and calculating RRs using separately the two types of controls was considered in both strata [16], 
whereas one study with 40% of hospital and 60% of population controls was excluded from the stratified analysis [86].
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different patterns of coffee intake (e.g. Asian, European, 
Northern American studies). We were not able to account 
for type of coffee beans (Robusta versus Arabica), brewing 
methods, preparation and cup size, characteristics that 
may influence the chemical composition of coffee, as 
the vast majority of the included studies did not provide 
such information. Only an early case-control study [62] 
and a recent cohort study [57] investigated separately 
the role of brewed/instant and filtered/boiled coffee on 
breast [57, 62] and ovarian cancer risk [57]. For breast 
cancer Schairer et al [62] did not find any association 
with either coffee type, whereas Nilsson and colleagues 
[57] reported decreased risk for boiled (overall) and 
filtered coffee (among postmenopausal women only) and 
increased risk for filtered coffee among pre-menopausal 
women. For ovarian cancer Nilsson et al [57] did not 
observe clear differences of the association of boiled and 
filtered coffee. 
Our study is the most up-to-date meta-analysis of 
breast and ovarian cancer as it includes articles published 
up to June 2016. Additional studies published up to 
January 2017 are for breast cancer two case-control 
studies by Cauchi et al (2016) [106] and Wielsoe et al 
(2016) [107] of 200 and 60 cases, which found RRs of 
0.90 (95% CI 0.81-1.00) for every cup/month of coffee 
intake and 0.52 (0.13; 2.07) for >3 cups/day versus 
<1 cup/day, respectively. For ovarian cancer, only one 
Canadian case-control study was published (Leung et al 
2016) including 524 cases and found a RR of 0.82 (95% 
CI 0.56-1.19) for >90 versus <50 adult lifetime cup-years 
of coffee. Thus, these studies will not materially modify our 
overall summary RR estimates.
Major strengths of our study are the in depth systematic 
review and the large number of studies included, allowing 
for several subgroup analyses. However, some limitations 
should also be acknowledged. The studies included in 
our meta-analysis may have various sources of bias. 
Misclassification of coffee consumption due to self-
reported assessment is likely in the original studies but 
this would be non-differential among cohort studies where 
information is collected long time before breast/ovarian 
cancer diagnosis. For case-control investigations, coffee 
assessment was based on patients’ reports which may be 
different from the reports by the control subjects. However, 
the similar RR estimates in case–control and prospective 
studies for both cancer sites are against such hypothesis. 
Also, recall of coffee drinking has been shown to be 
satisfactorily valid [109, 110]. 
Other types of selection or information bias in case-
controls studies cannot be excluded. For breast cancer, 
however, results were consistent among hospital-based, 
population-based case–control studies and prospective 
investigations, minimizing the probability of major bias that 
may have appreciably influenced our results. For ovarian 
cancer the apparent differentiation in RRs estimated 
for hospital-based and population-based case-control 
studies is probably attributed to earlier imprecise studies. 
Nevertheless the pooled associations for coffee intake were 
similar among population-based and cohort studies for this 
cancer site also. With respect to residual confounding, the 
well-accepted risk factors for breast and ovarian cancer 
were included in many studies, especially the most recent 
ones, and we used in our meta-analyses multivariate RRs 
adjusted for all available covariates. 
In conclusion, our systematic meta-analyses of case–
control and cohort studies provide strong, quantitative 
FIGURE 3. Cumulative meta-analysis for ovarian cancer for the highest versus the lowest coffee intake by year of publication.
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evidence to support the IARC evaluation that there is 
evidence suggesting lack of carcinogenicity of the female 
breast cancer due to coffee consumption, even at high 
doses. For ovarian cancer, there appears to be no 
association with coffee consumption, and the evidence 
is more inconsistent particularly with regards to the results 
of earlier studies, which is also in agreement with the 
IARC evaluation of ‘inadequate evidence’. Taken together 
the accumulated evidence regarding the association of 
coffee with endometrial cancer risk, this widely consumed 
beverage appears to be unrelated to women’s hormonal-
related cancer excess risk. 
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Supplementary
TABLE1. Details on handling specific studies in the stratified meta-analyses of coffee consumption with breast and ovarian 
cancer risk.
In the stratified analysis by menopausal status, a cohort of women ≥55 years of age at baseline [22] and a cohort in which over 96% of women 
were postmenopausal at baseline [59] were included in the stratum of post-menopausal breast cancer. For the stratified analysis by histological type of 
ovarian cancer the RRs for the New England Case Control (NECC) Study were considered from the publication by Kuper et al. [84], as the most recent 
publication by Kotsopoulos et al. [78] (included in the main analyses), did not provide such separate estimates.
In stratified analyses by BMI, for the Swedish Mammography cohort [41] and for the multicenter European Investigation into Cancer and nutrition 
cohort (EPIC) [21] cohort (included in the main analyses) we used the papers based on the same cohorts but with either shorter follow-up [48] or 
confined to Netherlands [54], since RRs according to BMI strata were not reported in the more complete articles. Normo-weight and overweight 
subjects were defined, respectively, as follows: body mass index (BMI) <25 versus ≥25 kg/m2 in two studies [51, 52], BMI ≤25 versus >25 kg/m2 
in two studies (48, 54), BMI <24 versus ≥24 kg/m2 in one study [43], and BMI ≤26.5 versus >26.5 kg/m2 in one study [40] . For the Ganmaa 
et al [51] study which reported RRs for coffee intake in the BMI 25-29 and ≥30 kg/m2 strata, a summary RR for overweight women was obtained by 
pooling the indicated RRs with a fixed effects model. Similarly, in the study by Tavani et al [40] RRs in the strata of BMI <23.2 kg/m2 and 23.2-26.5 
kg/m2 were pooled in order to generate a result for normo-weight women
FIGURE 1. Selection strategy to identify studies that were included in the meta-analysis of coffee intake with breast and ovarian 
cancer risk.
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FIGURE 3. Funnel plot for the assessment of publication bias in the 40 studies included in the meta-analysis of coffee intake with 
breast cancer risk (p for Egger test 0.877; p for Begg test 0.753). Dashed diagonal lines indicate 95% CI
FIGURE 2. Relative risks (RRs) and 95% confidence intervals (CI) of breast cancer for the highest versus the lowest decaffeinated 
coffee drinking category. The combined RRs and 95% CI were calculated using the random-effects models.
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FIGURE 5. Funnel plot for the assessment of publication bias in the 31 studies included in the meta-analysis of coffee intake with 
ovarian cancer risk (p for Egger test 0.008; p for Begg test 0.008).  Dashed diagonal lines indicate 95% CI.
FIGURE 4. Relative risks (RRs) and 95% confidence intervals (CI) of ovarian cancer for the highest versus the lowest decaffeinated 
coffee drinking category. The combined RRs and 95% CI were calculated using the random-effects models.
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